NASDAQ:SPPI
Delisted
Spectrum Pharmaceuticals Stock News
$1.03
+0 (+0%)
At Close: Oct 30, 2023
Penny Stocks To Buy: The Good, Bad, & Ugly & 3 To Watch Now
06:37pm, Friday, 09'th Sep 2022
Whether you're a seasoned trader making money with penny stocks or just
Spectrum Pharmaceuticals (SPPI) Q2 2022 Earnings Call Transcript
07:30am, Friday, 12'th Aug 2022 The Motley Fool
SPPI earnings call for the period ending June 30, 2022.
Spectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q2 2022 Results - Earnings Call Transcript
11:44am, Thursday, 11'th Aug 2022
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Michael Grabow - SVP, Corporate Strategy and Operations Thomas J. Riga -
Spectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update
07:00am, Friday, 29'th Jul 2022
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference cal
Liminal (LMNL) Ends Development of Lead Candidate, Stock Down
01:46pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Based on results from an early-stage study, Liminal BioSciences (LMNL) decides to discontinue the development of its lead pipeline candidate, fezagepras.
Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M
01:47pm, Friday, 15'th Jul 2022 Zacks Investment Research
Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
02:59pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
02:53pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
02:32pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Best Momentum Stocks to Buy for July 13th
02:00pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
Best Momentum Stocks to Buy for July 13th
11:32am, Wednesday, 13'th Jul 2022
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
New Strong Buy Stocks for July 13th
11:00am, Wednesday, 13'th Jul 2022 Zacks Investment Research
KMI, UFCS, GKOS, SPPI and BECN have been added to the Zacks Rank #1 (Strong Buy) List on July 13, 2022.
New Strong Buy Stocks for July 13th
08:29am, Wednesday, 13'th Jul 2022
KMI, UFCS, GKOS, SPPI and BECN have been added to the Zacks Rank #1 (Strong Buy) List on July 13, 2022.
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
03:14pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Hot Penny Stocks Under $1 To Watch In June
07:56pm, Thursday, 02'nd Jun 2022 PennyStocks
Penny stocks to watch under $1 right now
The post Hot Penny Stocks Under $1 To Watch In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
